IOWA | Health and Human Services

Iowa Medicaid Drug Utilization Review (DUR) Commission

November 6, 2024

Time: 9:30 a.m. – 1:30 p.m. CT
Location: Virtual Only
Teams Link: https://teams.microsoft.com/l/meetup-join/19%3ameeting_NGRjNDYxMWMtNDQ0ZS00NTI1LTk4OTItYjI4ODFlYjU0MWU4%40thread.v2/0?context=%7b%22Tid%22%3a%228d2c7b4d-085a-4617-8536-38a76d19b0da%22%2c%22Oid%22%3a%22982a0572-2333-4ea7-b2e0-b02af2367c61%22%7d

Final Agenda

1. Welcome & Introductions
    a) Commission Members and Staff
2. Commission Business
    a) Approval of the August 7, 2024 Meeting Minutes
    b) August 2024 DUR Recommendation Letter to DHHS
    c) Follow-Up from Previous Meeting(s)
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
    a) Iowa Total Care
    b) Molina Healthcare of Iowa
    c) Wellpoint Iowa
    d) Fee-for-Service
    e) Comparative Summary
5. Public Comment* (See attached Conflict of Interest Disclosure)
    - Verbal - Must **pre-register** to provide verbal public comment and submit a completed conflict of interest disclosure. *For hybrid meetings, verbal public comment will be allowed in person and virtually*.
    - Written – Must submit written comments and a completed conflict of interest disclosure.
    - **All submissions must be received no later than 4:30 p.m. CST October 30, 2024.**
    - **Email to pba_iadur@optum.com.**
6. Retrospective DUR
    a) Data Presentation(s)
        i. Stimulant Medication Utilization without Supporting Diagnosis
        ii. Monitoring Prescribing of Antipsychotic Medications in Adults
        iii. Triple Therapy – Opioid, Benzodiazepine, and Muscle Relaxant
    b) Proposal(s)
        i. 72-Hour Emergency Override Utilization Review
        ii. Concurrent Use of GLP-1 Receptor Agonist and DPP-4 Inhibitor
    c) Commission Recommendations for Retrospective DUR Agenda Topics
7. Break (10 minutes)
8. Prior Authorization
    a) Annual Review of Prior Authorization Criteria

b) Ensifentrine (Ohtuvayre) – Initial Review
c) Select Preventative Migraine Treatments – Initial Review
d) Topical Roflumilast (Zoryve) – Initial Review
e) Vonoprazan (Voquezna) – Initial Review
f) Dupilumab (Dupixent) – Initial Review
g) Biologicals for Inflammatory Bowel Disease – Second Review
h) Incretin Mimetics for Non-Diabetes Indications – Second Review
i) Janus Kinase Inhibitors – Second Review
j) Maralixibat (Livmarli) – Second Review
k) Omalizumab (Xolair) – Second Review
l) Oral Glucocorticoids for Duchenne Muscular Dystrophy – Second Review
m) Tralokinumab (Adbry) - Second Review
n) Zuranolone (Zurzuvae) – Second Review

9. Miscellaneous
    a) DUR Digest Vol. 37, No. 1 – Initial Review
10. MedWatch

FDA Approves First Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose
FDA Approves First Nasal Spray for Treatment of Anaphylaxis
FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause
FDA Approves First Treatment for Niemann-Pick Disease, Type C
FDA Approves Second Treatment for Niemann-Pick Disease, Type C
FDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration
FDA is alerting patients and health care professionals about the voluntary withdrawal of Oxbryta from the market due to safety concerns
FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment must register and complete a conflict-of-interest disclosure. Registration and completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at pba_iadur@optum.com. Speakers who fail to submit their conflict-of-interest disclosure on time will have their request to speak denied or will not have their written comments shared.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at pba_iadur@optum.com or (515) 974-3131.

Next Meeting
February 5, 2025
Meeting Format: Virtual